Comparative Pharmacology
Head-to-head clinical analysis: NALTREXONE HYDROCHLORIDE versus ZIMHI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALTREXONE HYDROCHLORIDE versus ZIMHI.
NALTREXONE HYDROCHLORIDE vs ZIMHI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at mu, kappa, and delta opioid receptors, with highest affinity for mu receptors. Also acts as an antagonist at the toll-like receptor 4 (TLR4).
Opioid receptor antagonist; reverses opioid effects by competitively binding to mu-opioid receptors.
50 mg orally once daily for opioid dependence; 25 mg orally once daily for alcohol dependence, may increase to 50 mg after one week.
5 mg intramuscularly every 2-3 minutes as needed; maximum 3 doses.
None Documented
None Documented
Terminal elimination half-life: ~4 hours for naltrexone; its major active metabolite, 6-β-naltrexol, has a half-life of ~13 hours. The longer half-life of the metabolite contributes to sustained receptor blockade.
Terminal half-life: 2.5-4 hours; clinical context: short duration requires repeat dosing for sustained opioid effects.
Renal: primarily as unchanged drug (<2%) and metabolites (mainly 6-β-naltrexol, glucuronide conjugates); approximately 60% of dose excreted in urine (including metabolites) and about 30% in feces via biliary excretion.
Renal: 30-35% unchanged; biliary/fecal: 50-60% as metabolites.
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist